Clinical Trial Update: A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BIBF 1120 in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED